Belite Bio, Inc. · NASDAQ:BLTE
Belite Bio — Q4 2025 Earnings Presentation
8 slides from Belite Bio's earnings presentation, Mar 2, 2026
Slide 1: Q4 and FYE 2025 Financial Results Conference Call
Q4 and FYE 2025 Financial Results Conference Call March 2, 2026, 4:30 p.m. ET Nasdaq: BLTE For more info, please visit: www.belitebio.com
Slide 2: Belite Bio Participants
Belite Bio Participants Belite Management Team Tom Lin, MMED, PhD, MBA Hendrik Scholl, MD, MA Nathan Mata, PhD Hao-Yuan Chuang, CFA, MBA, FRM (Chairman, CEO) (CMO) (CSO) (CFO) • 16+ years of executive management • 25+ years of expertise in treating retinal • 15+ years of ophthalmic drug • 16+ years
Slide 3: Forward-Looking Statements and Legal Disclaimer
Forward-Looking Statements and Legal Disclaimer This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire,
Slide 4: Belite Bio Pipeline Overview & Updates
Belite Bio Pipeline Overview & Updates PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Stargardt Disease (STGD1) • Ph2, 2-year treatment, completed (13 subjects) • Ph3, 2-year treatment, global trial (“DRAGON” Study), completed (104 subjects) Tinlarebant • Ph2/3, 2-year treatment, global trial (“DRAGON II”
Slide 5: Q4 2025 Financial Results
Q4 2025 Financial Results For more info please visit: www.belitebio.com
Slide 6: 2025 Fourth-Quarter Financial Results
2025 Fourth-Quarter Financial Results For the Three Months Ended December 31 For the Three Months Ended December 31 (In thousand USD) (GAAP) (Non-GAAP) 2024 2025 2024 2025 Total operating expenses 11,457 28,077 7,251 16,362 - R&D 7,254 14,624 5,744 12,172 - SG&A 4,203 13,453 1,507 4,190 Net loss (10
Slide 7: 2025 Full Year Financial Results
2025 Full Year Financial Results For the years ended December 31 For the years ended December 31 (In thousand USD) (GAAP) (Non-GAAP) 2024 2025 2024 2025 Total operating expenses 39,996 84,208 31,009 45,289 - R&D 29,939 45,377 26,164 36,230 - SG&A 10,057 38,831 4,845 9,059 Net loss (36,144) (77,611)
Slide 8: Q&A
Q&A For more info please visit: www.belitebio.com